THYROID CANCERS

September 24th 2024

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a community oncologist should be aware of.

September 13th 2024

The study found that lenvatinib continued to demonstrate improved efficacy in patients with radioiodine-refractory differentiated thyroid cancer.

September 13th 2024

Data from the phase 2 PECATI trial support the use of lenvatinib plus pembrolizumab as a potential standard treatment for patients with advanced B3-thymoma and thymic carcinoma.

August 12th 2024

Selpercatinib led to high response and progression-free survival rates among patients who were treatment naive and pretreated with RET-altered thyroid cancers.